StockNews.com Initiates Coverage on Horizon Therapeutics Public (NASDAQ:HZNP)

Equities research analysts at StockNews.com began coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) in a research report issued on Saturday. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Separately, TheStreet downgraded shares of Horizon Therapeutics Public from a “b-” rating to a “c+” rating in a report on Monday, May 8th. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Horizon Therapeutics Public currently has an average rating of “Hold” and a consensus target price of $111.42.

Horizon Therapeutics Public Stock Up 0.9 %

Shares of HZNP stock opened at $111.00 on Friday. The stock has a 50 day moving average of $110.01 and a 200-day moving average of $104.02. Horizon Therapeutics Public has a 12 month low of $57.84 and a 12 month high of $113.83. The company has a quick ratio of 3.89, a current ratio of 4.07 and a debt-to-equity ratio of 0.50. The firm has a market cap of $25.38 billion, a PE ratio of 69.81, a price-to-earnings-growth ratio of 4.23 and a beta of 1.13.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last announced its quarterly earnings data on Wednesday, May 3rd. The biopharmaceutical company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $1.17 by ($0.34). Horizon Therapeutics Public had a return on equity of 20.31% and a net margin of 10.40%. The firm had revenue of $832.10 million for the quarter, compared to analyst estimates of $897.06 million. During the same period in the previous year, the business posted $1.34 EPS. Horizon Therapeutics Public’s revenue for the quarter was down 6.0% compared to the same quarter last year. On average, equities analysts predict that Horizon Therapeutics Public will post 5.31 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ieq Capital LLC lifted its position in Horizon Therapeutics Public by 6.6% during the first quarter. Ieq Capital LLC now owns 2,173 shares of the biopharmaceutical company’s stock valued at $237,000 after purchasing an additional 135 shares during the last quarter. Vanguard Personalized Indexing Management LLC raised its position in Horizon Therapeutics Public by 0.7% in the 1st quarter. Vanguard Personalized Indexing Management LLC now owns 21,445 shares of the biopharmaceutical company’s stock worth $2,341,000 after buying an additional 141 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Horizon Therapeutics Public by 6.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,302 shares of the biopharmaceutical company’s stock worth $262,000 after purchasing an additional 145 shares during the period. Profund Advisors LLC boosted its position in Horizon Therapeutics Public by 0.6% in the fourth quarter. Profund Advisors LLC now owns 25,277 shares of the biopharmaceutical company’s stock worth $2,877,000 after purchasing an additional 156 shares during the last quarter. Finally, Quent Capital LLC boosted its position in Horizon Therapeutics Public by 8.8% in the third quarter. Quent Capital LLC now owns 1,969 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 160 shares during the last quarter. Institutional investors own 91.01% of the company’s stock.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.